|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Reference and Year** | **Cohort** | **Age ±SD**  **(years)** | **Results** | **Take home message** |
| DeFina *et al.*20191 | 21,758 Active Men  - 16,447: <1500 MET-Min/Week  - 3750: 1500-2999 MET-Min/Week  - 1561: >3000  MET-Min/Week | 51.7  ±8.4 | Men with the highest exercise dose i.e. >3000 MET-min/week had the greatest prevalence of a CAC>100 AU, followed by those exercising <1500 MET-min/week and lastly 1500-2999 MET-min/week i.e. 27.7% vs. 24.5% vs: 22.6%, respectively; there was no increase in all-cause or cardiovascular disease mortality. | There is a dose response relationship between exercise dose and CAC score in older active men which has not translated to increased all-cause or cardiovascular disease mortality. |
| Aengevaeren *et al.* 20172 | 284 Male Lifelong Athletes (Competitive & Recreational)  - *Group 1*: 88 exercise volume <1000 MET-min/week  - *Group 2*: 121 between 1000-2000 MET-min/week  -*Group 3*: 75 >2000 MET-min/week | 54±6  55±6  56±7 | - Athletes with the highest exercise dose (group 3) had the greatest prevalence of a CAC>0 AU, followed by group 2 and group 1 i.e. 43% vs. 50% vs. 68%, respectively.  - Athletes with the highest exercise dose were also most likely to have calcified plaques – Group 1: 62% vs. Group 2: 59% vs. Group 3: 70%. | There is a relationship between exercise dose and CAC and calcified coronary plaques. |
| Merghani *et al.* 20173 | - 152 low Framingham risk, Runners and Cyclists (106 Male, 46 Female), exercise volume 8±4 hrs/week 31±13 years.  - 92 age-, gender- and risk score matched controls (54 Male, 38 Female), exercise volume 1.9±0.5 hrs/week | 54.4  ±8.5 | - 18.9% of male athletes had a CAC>100 AU vs. 7.4% of male controls.  - 11% of male athletes had a CAC > 300 AU compared with none of the controls.  - There were no differences in CAC between female athletes and controls.  - Male athletes were more likely to have calcified plaques than controls i.e. 72.7% vs. 30.8%. | Male master endurance athletes have a greater prevalence of high CAC scores but more stable coronary plaque morphology than controls. |
| Dores *et al.* 20184 | 105 Male Athletes (≥4 hour/week ≥5years | ≥40 | - 9.5% of athletes had a CAC>100 AU.  - 12.4% of athletes had a CAC> 75th Centile.  - 41.9% of athletes demonstrated coronary plaque.  - 5.7% of athletes had obstructive CAD. | Cardiac CT provides additional data for risk stratification of master athletes over and above risk factor evaluation and exercise testing. |
| Braber *et al.* 20165 | 318 Asymptomatic, CVD free, Male Competitive and Recreational Athletes | ≥45 | - 52.5% of athletes had a CAC>0 AU.  - 16.3% of athletes had a CAC>100 AU.  - 5.3% of athletes had a stenosis >50%. | Occult CAD is common to more than half of male master athletes despite normal risk factor evaluation and exercise testing. |
| Möhlenkamp *et al.* 20086 | *- Group I*: 108 Male Marathon Runners  (4686±2285 METs/week)  *- Group 2*: 864 age-matched controls  (1389±1876 METs/week)  *- Group 3*: 216 age- and risk- matched controls  (1748±2200 METs/week) | 57±6 | - Athletes (group 1) had an equal prevalence of a CAC>100 AU compared to age-matched (group 2) controls but a greater prevalence than age and risk-matched controls (group 3) i.e. group 1: 36.1% vs. group 2: 36.34% vs. group 3: 21.8%.  - Athletes had a greater prevalence of CAC >75th centile than age-matched controls (p=0.85) but a lower prevalence than age and risk-matched controls (p=0.01) i.e. Group 1: 25% vs. Group 2: 24.2% vs. Group 3: 14.8%. | Male master endurance athletes have a greater prevalence of high CAC scores than age- and risk-matched controls. |
| Jafar *et al.* 20197 | 56 Runners  (37 Male, 19 Female)  *- Group A* (n=21): >10 Ultramarathons or ironman/10 years  *- Group B* (n=9): >9 marathons/10 years  - *Group C* (n=26) >9 years shorter races/10 years | ≥45 | - Athletes with the highest exercise dose i.e. group A+B had a greater prevalence of a CAC>100 AU than group C i.e. 33% vs. 12% (p=0.05).  - Athletes with the highest dose of exercise had a greater prevalence of a CAC score > 50th percentile i.e. 70% vs. 19% (p=0.001). | There is a dose response relationship between exercise dose and CAC score and atherosclerotic plaques in master athletes. |
| Roberts *et al.* 2017*8* | 50 Male Marathon Runners ≥1 marathon/year for >25 consecutive years | 59±7 | - 68% of runners had a CAC>0 AU.  - 44% of runners had a CAC>100 AU. | Male marathon runners have a high prevalence of CAD however this was not associated with the number of marathons run. |
| Tsiflikas *et al.* 20159 | 50 Male Marathon Runners, mean PROCAM score 1.85% | 52.7  ±5.9 | - 52% of runners had a CAC=0 AU and no CAD  - 40% of runners had a CAC>0 AU and a coronary stenosis <50%  - 6% of runners had a CAC>0 AU and stenosis >50%  - 2% of runners had a CAC>0 and stenosis >75% | Occult CAD detected by CT is common to more than half of low risk male marathon runners however only a small number have obstructive disease. |
| Roberts *et al.* 201710 | - 26 female marathon runners, ≥1 marathon/year for 10-25 years  - 28 sedentary controls | 56±10  61±10 | - Runners had a lower prevalence of calcified coronary plaque than controls i.e. 19.2% vs. 50%. (p=0.014)  - Runners had a lower total calcified coronary plaque volume than controls i.e. 43mm3 vs. 77mm3. (p=0.014) | Female marathon runners had a low prevalence of CAC and calcified plaque volume and significantly lower than controls. |
| Karlstedt *et al.* 201211 | 25 low-risk elite marathon runners (21 Male, 4 Female), 75±11 km/week | 55±4 | - 2 (8%) runners had a >70% stenosis in the left anterior descending artery. | A small but important number of elite low-risk marathon runners demonstrate obstructive coronary disease |

**Table 1.** Summary ofnoteworthy studies investigating the relationship between CAC score and CCTA findings amongst master athletes and active individuals.

**References**

1. DeFina LF, Radford NB, Barlow CE, Willis BL, Leonard D, Haskell WL, Farrell SW, Pavlovic A, Abel K, Berry JD, Khera A, Levine BD. Association of All-Cause and Cardiovascular Mortality With High Levels of Physical Activity and Concurrent Coronary Artery Calcification. *JAMA Cardiology* 2019.

2. Aengevaeren VL, Mosterd A, Braber TL, Prakken NHJ, Doevendans PA, Grobbee DE, Thompson PD, Eijsvogels TMH, Velthuis BK. Relationship Between Lifelong Exercise Volume and Coronary Atherosclerosis in Athletes. *Circulation* 2017;**136**:138–148.

3. Merghani A, Maestrini V, Rosmini S, Cox AT, Dhutia H, Bastiaenan R, David S, Yeo T-J, Narain R, Malhotra A, Papadakis M, Wilson MG, Tome M, AlFakih K, Moon JC, Sharma S. Prevalence of Subclinical Coronary Artery Disease in Masters Endurance Athletes With a Low Atherosclerotic Risk Profile. *Circulation* 2017;**136**:126–137.

4. Dores H, de Araújo Gonçalves P, Monge J, Costa R, Tátá L, Malhotra A, Sharma S, Cardim N, Neuparth N. Subclinical coronary artery disease in veteran athletes: is a new preparticipation methodology required? *Br J Sports Med*; 2020 Mar;54(6):349-353

5. Braber TL, Mosterd A, Prakken NH, Rienks R, Nathoe HM, Mali WP, Doevendans PA, Backx FJ, Bots ML, Grobbee DE, Velthuis BK. Occult coronary artery disease in middle-aged sportsmen with a low cardiovascular risk score: The Measuring Athlete’s Risk of Cardiovascular Events (MARC) study. *Eur J Prev Cardiol* 2016;**23**:1677–1684.

6. Möhlenkamp S, Lehmann N, Breuckmann F, Bröcker-Preuss M, Nassenstein K, Halle M, Budde T, Mann K, Barkhausen J, Heusch G, Jöckel K-H, Erbel R, Marathon Study Investigators, Heinz Nixdorf Recall Study Investigators. Running: the risk of coronary events : Prevalence and prognostic relevance of coronary atherosclerosis in marathon runners. *European Heart Journal*; 2008;**29**:1903–1910.

7. Jafar O, Friedman J, Bogdanowicz I, Muneer A, Thompson PD, Ling J, Messina A, Yen M, Wakefield D, Varanasi P, Haleem K. Assessment of Coronary Atherosclerosis Using Calcium Scores in Short- and Long-Distance Runners. *Mayo Clin Proc Innov Qual Outcomes* 2019;**3**:116–121.

8. Roberts WO, Schwartz RS, Garberich RF, Carlson S, Knickelbine T, Schwartz JG, Peichel G, Lesser JR, Wickstrom K, Harris KM. Fifty Men, 3510 Marathons, Cardiac Risk Factors, and Coronary Artery Calcium Scores. *Med Sci Sports Exerc* 2017;**49**:2369–2373.

9. Tsiflikas I, Thomas C, Fallmann C, Schabel C, Mangold S, Ketelsen D, Claussen CD, Axmann D, Schroeder S, Burgstahler C. Prevalence of Subclinical Coronary Artery Disease in Middle-Aged, Male Marathon Runners Detected by Cardiac CT. *Rofo*; 2015;**187**:561–568.

10. Roberts WO, Schwartz RS, Kraus SM, Schwartz JG, Peichel G, Garberich RF, Lesser JR, Oesterle SN, Wickstrom KK, Knickelbine T, Harris KM. Long-Term Marathon Running Is Associated with Low Coronary Plaque Formation in Women. *Med Sci Sports Exerc* 2017;**49**:641–645.

11. Karlstedt E, Chelvanathan A, Da Silva M, Cleverley K, Kumar K, Bhullar N, Lytwyn M, Bohonis S, Oomah S, Nepomuceno R, Du X, Melnyk S, Zeglinski M, Ducas R, Sefidgar M, Mackenzie S, Sharma S, Kirkpatrick ID, Jassal DS. The impact of repeated marathon running on cardiovascular function in the aging population. *J Cardiovasc Magn Reson*; 2012;**14**:58.